Liposome Size Research Articles

Microfluidic Approach for Enhanced Paeoniflorin Transdermal Delivery: A Comparative Study on Different Chips and Mixing Dynamics

Paeoniflorin is a natural pharmaceutical ingredient with a widely biological activity. However, as a hydrophilic drug, the problem of low transdermal rate limits its clinical application. To overcome this shortage, LUVs were used as biocompatible carriers of paeoniflorin in this study. We prepared paeoniflorin-loaded large unilamellar vesicles (LUVs) with W/O/W structure by microfluidics. We used four kinds of chips to prepare paeoniflorin LUVs and explored the effects of the chip structures on LUVs properties applying both experiments and numerical simulations. The difference of fluid mixing mechanisms was analyzed among four different channels, including straight and curved structures. Then we evaluated the differences in skin permeability among the three groups, paeoniflorin aqueous solution group, drug-loaded liposome group and blank liposome & drug mixture group, using the abdominal skin of male mice. The results showed that the structure of the microfluidic channel was a key factor affecting the flow rate and mixing efficiency. The mixing efficiency further affected the liposome size. The mixing efficiency of curved channel was not better than that of a straight channel due to the low flow rate and long mixing time. By the results of transdermal experiments, LUVs could reduce the transdermal time and increase the total transdermal amount. LUVs effectively improved the transdermal absorption efficiency of paeoniflorin. In conclusion, paeoniflorin LUVs with highly efficient transdermal were successfully prepared by using microfluidics. We explored the underlying fluid dynamics that lead to variations in the preparation with different chip structures. The transdermal effect of the LUVs was verified.Graphical

DNA-Assisted Assays for Studying Lipid Transfer Between Membranes.

Extended-synaptotagmins (E-Syts) are proteins located on the endoplasmic reticulum (ER) that tether the ER to the plasma membrane (PM) and regulate their lipid homeostasis via its lipid transfer module, the synaptotagmin-like mitochondrial lipid-binding protein (SMP) domain. Here, we describe in vitro DNA nanostructure-assisted lipid transfer assays investigating how the SMP domain transports lipids between membranes and associates with the membranes to extract and release lipids. The lipid transfer signal was detected through fluorescence resonance energy transfer (FRET). This method overcomes the limitations of commonly used lipid transfer assays in accurately controlling inter-liposome distance and liposome size, enabling us to further understand the details involved in the process of SMP domain-mediated lipid transfer. Similar platforms can be extended to studying the lipid transfer distance and membrane curvature sensitivity of other lipid transfer proteins.

Cm-p5, a molluscan-derived antifungal peptide exerts its activity by a membrane surface covering in a non-penetrating mode

Amidst the health crisis caused by the rise of multi-resistant pathogenic microorganisms, Antimicrobial Peptides (AMPs) have emerged as a potential alternative to traditional antibiotics. In this sense, Cm-p5 is an AMP with fungistatic activity against the yeast Candida albicans. Its antimicrobial activity and selectivity have been well characterized; however, the mechanism of action is still unknown. This study used biophysical approaches to gain insight into how this peptide exerts its activity. Stability and fluidity of lipid membrane were explored by liposome leakage and Laurdan generalized polarization (GP) respectively, suggesting that Cm-p5 does not perturb lipid membranes even at very high concentrations (≥100µm.L-1). Likewise, no depolarizing action was observed using 3,3'-propil-2,2'-thyodicarbocianine, a potential membrane fluorescent reporter, with C. albicans cells or the corresponding liposome models. Changes in liposome size were analyzed by Dynamic Light Scattering (DLS) data, indicating that Cm-p5 covers the vesicular surface slightly increasing liposome hydrodynamic size, without liposome rupture. These results were further corroborated with Langmuir monolayer isotherms, where no significant changes in lateral pressure or area per lipid were detected, indicating little or no insertion. Finally, data obtained from molecular dynamics simulations aligned with in vitro observations, whereby Cm-p5 slightly interacted with the fungal membrane model surface without causing significant perturbation. These results suggest Cm-p5 is not a pore-forming anti-fungal peptide and that other mechanisms of action on the membrane as some limitation of fungal nutrition or receptor-dependent transduction for depressing growth development should be explored.

Surface-modified liposomal in-situ nasal gel enhances brain targeting of berberine hydrochloride for Alzheimer's therapy: optimization and in vivo studies.

This work aimed to formulate surface-modified berberine hydrochloride (BER)-loaded liposomes containing in-situ nasal gel for bran targeting. The liposomes were prepared by ethanol-injection method and optimized following a 32 full-factorial design. Size, morphology, zeta potential, ex-vivo permeation, and in-vitro release were estimated. The surface of optimized liposome was modified with ascorbic acid. The size of surface-modified liposomes was bigger (191.4 nm) than the unmodified liposomes (171 nm). Surface-modified liposomes were embedded in in-situ gel using poloxamer and Carbopol 934P. Liposomal in-situ gel showed higher permeation (71.94%) in contrast to the plain gel (46.64%). In-vivo pharmacokinetic examination of payload from liposomal in-situ gel displayed higher concentration in brain (Cmax of 93.50 ng/mL). The liposomal in-situ nasal gel had a higher drug targeting efficiency (138.43%) and a higher drug targeting potential (27.77%) confirming improved brain targeting. In male Wistar rats, the pharmacodynamic parameters (path length and escape latency) were evaluated with trimethyl tin-induced neurodegeneration. Animals treated with BER-loaded in-situ gel significantly decreased escape latency and path length in comparison to the control group. Histopathological assessment showed that the formulated gel was safe for intranasal administration. The developed formulation has the potential to effectively enhance the efficacy of BER in Alzheimer's disease management.

Liposomes – metabolically active drug transport systems: visualization and pharmacokinetic. Part 2 (review)

Introduction. In the second part of the review we discussed aspects of visualization, pharmacokinetics and biodistribution of liposomes.Text. Many different methodsh as been proposed for the visualization of liposoms morphology and quality such as light microscopy, ESEM, TEM, AFM, etc. Each method have own advantages and limitations which are discussed in the article: In general, the selection of method depends on the specific morphological characteristics and level of details. It is important to understand the specificity of the liposomes and the visualization method for correct preparation of samples. Adequately performed pharmacokinetic and biodistribution studies can also be used as a tool for liposome visualization. The nature of active pharmaceutical ingredients, dose, lipid components, size of liposomes, charge, coating of liposomes with excipients and route of administration significantly affects the pharmacokinetics of liposomal forms. Additionally, the interaction of liposomal forms with the immune system, reticuloendothelial system and blood components play an important role in their absorption, distribution and elimination.Conclusion. The better understanding of the absorption, biodistribution, metabolism and clearance of liposomal formulations is essential for the development of modern drugs.

Leveraging machine learning to streamline the development of liposomal drug delivery systems

Drug delivery systems efficiently and safely administer therapeutic agents to specific body sites. Liposomes, spherical vesicles made of phospholipid bilayers, have become a powerful tool in this field, especially with the rise of microfluidic manufacturing during the COVID-19 pandemic. Despite its efficiency, microfluidic liposomal production poses challenges, often requiring laborious, optimization on a case-by-case basis. This is due to a lack of comprehensive understanding and robust methodologies, compounded by limited data on microfluidic production with varying lipids. Artificial intelligence offers promise in predicting lipid behaviour during microfluidic production, with the still unexploited potential of streamlining development. Herein we employ machine learning to predict critical quality attributes and process parameters for microfluidic-based liposome production. Validated models predict liposome formation, size, and production parameters, significantly advancing our understanding of lipid behaviour. Extensive model analysis enhanced interpretability and investigated underlying mechanisms, supporting the transition to microfluidic production. Unlocking the potential of machine learning in drug development can accelerate pharmaceutical innovation, making drug delivery systems more adaptable and accessible.

Glibenclamide-encapsulated Liposomes alleviate LPS-induced Inflammatory Cascade through NLRP3 inhibition in macrophages

Abstract Inflammation is a vital immune response for survival during infection and tissue damage. It is critical in maintaining normal tissue homeostasis by orchestrating appropriate inflammatory mediators. Macrophages, integral to innate immunity, respond to lipopolysaccharide (LPS) present in gram-negative bacteria by releasing inflammatory cytokines. Utilizing nanotechnology for drug delivery have been proven with enhanced therapeutic approaches by targeting the suppression of inflammatory mediators and cytokines. Recent studies have provided insights into the role of inflammasomes in intracellular processes linked to inflammation. Glibenclamide (GLB), a sulfonylurea used in type 2 diabetes treatment, has emerged as a potent inhibitor of the NLRP3 inflammasome, showing promise in alleviating inflammation-associated injuries. To overcome the limitations of GLB, such as low aqueous solubility and high permeability, in this study, methyl-PEG-DSPE lipids were used to develop GLB-loaded nanoliposomes. The size of blank liposome was measured to be 120 nm. Anionic GLB-loaded liposomes, sized 146 nm with spherical morphology, effectively suppressed the expression of NLRP3 mediators (caspase-1, ASC, IL-1B, and IL-18) and various reactive oxygen species mediators compared to free GLB, reducing LPS-induced inflammatory responses in RAW264.7 macrophages. This suggests the potential of GLB-loaded liposomes as a therapeutic agent for inflammation-related disorders, warranting further in-vivo investigation.

Effect of Solvent and Cholesterol on Liposome Production by the Reverse-Phase Evaporation (RPE) Method.

Liposomal drug delivery is a promising approach for delivering therapeutics effectively. While most liposomes are designed to be nanometer-sized for efficient cellular uptake, micron-sized liposomes are gaining interest due to their larger drug-loading capacity. When combined with macroscale structures, such as implants and hydrogels, they offer prolonged therapeutic delivery. This study investigates how solvents affect the production of micron-sized liposomes, with or without cholesterol, using the reverse-phase evaporation (RPE) method. Although the RPE method is established for producing micron-sized liposomes, the influence of solvents on liposome size and uniformity is not well understood. The study explores whether controlling the size of inverse micelles, an intermediate product, through the use of different organic solvents affects the final liposome size. Three solvents─diethyl ether, methanol, and acetone─were tested for their effect on the formation of inverse micelles and liposomes and their sizes. Results showed that without cholesterol, diethyl ether produced uniform inverse micelles, leading to mostly nanosized liposomes. Methanol and acetone resulted in phase separation, preventing uniform liposome formation, although some micron-sized liposomes appeared. The acetone sample yielded mostly oil droplets. The results showed that forming inverse micelles lead to nanosized liposomes. With cholesterol, phase separation was dominant in methanol, but micron-sized liposomes still formed. Across all cases, cholesterol reduced the liposome size. The findings reveal that inverse micelles are not always reliable predictors of the final liposome size and that the RPE method is highly sensitive to solvent polarity and lipid-solvent interactions. Overall, the findings of this study provide valuable insights into how the choice of solvent and lipid composition can influence the production of liposomes via the RPE method. These insights are critical for optimizing liposome production and influencing future designs of liposomal drug delivery systems.

Applications of radionuclide-carrying liposomes for diagnosis and treatment of cancer

Using nanocapsules to deliver diagnostic and therapeutic agents to targeted biological sites enhances the safety and effectiveness of healthcare by decreasing toxicity and increasing the accumulation of medicinal agents at targeted sites. Liposomes, nanocapsules made of naturally occurring lipids, boast many advantages for the delivery of therapeutic agents. This article reviews both the advantages and challenges associated with liposomal drug delivery for the treatment of cancerous tumors and infectious diseases. These minute spherical sacs of phospholipid molecules are flexible carriers that can be modified in various ways to optimize their use. Examples of this include alteration of the size of liposomes to selectively accumulate in tumor microenvironments and “PEGylation” of their surface to reduce uptake of liposomes by the mononuclear phagocytic system (MPS). While one of the main challenges of liposomal drug delivery is the heightened uptake of liposomes by the MPS, this unique property can be used to target diseased areas with a significant MPS presence. Furthermore, the liposomal structure can be manipulated to allow for the triggered release of internal contents with externally controlled factors. Liposomes carrying therapeutic radionuclides can be injected directly into solid tumors and dispersed throughout the tumor by convection-enhanced delivery. The flexibility and pliability of liposomes allow them to move through tight spaces within a tumor with much greater dispersion and penetration when compared to more rigid nanoparticles. Due to the benefits of radionuclide-carrying liposomes in disease diagnosis and delivery of chemotherapeutic agents, their utilization is expected to be expanded.

Ultrafast continuous flow-dialysis for nanoparticle-based drug delivery systems via microfluidic-multiple buffer injector

Nanoparticle-based drug delivery systems (NP-DDS) have emerged as promising carriers for bioactive organic molecules due to their potential in enhancing therapeutic effects. However, traditional purification methods like batch dialysis and diafiltration can alter NP-DDS bio-physicochemical properties due to the lengthy process, prolonged coexistence with organic solvents, and external forces. To address this challenge, we developed an ultrafast flow-dialysis microfluidic module with dual channels separated by a membrane layer. The module leverages multiple buffer injectors (MBIs) to accelerate dialysis by injecting fresh buffer into multiple dialysis zones of bottom channel, refreshing the concentration gradients over the mixture sample in the upper channel to maximize mass transfer efficiency. Using this method for a dual drug-loaded liposome sample containing doxorubicin and curcumin, impurities (such as ethanol and un-trapped drugs) removal and buffer exchange were rapidly terminated within 15 min, continuously operating for ∼ 6 hrs with sequential membrane regeneration process. Importantly, unlike traditional methods, the MBI process maintains the initial uniformity in the size and distribution of liposomes with no leakage of the encapsulated drugs. In vitro HeLa cell tests reveal that the liposomes purified by MBI exhibited significantly higher cellular uptake (1.13 ∼ 1.67 fold), presumably due to the small and uniform size of liposomes, leading to improved anti-tumor effects. Notably, the MBI platform’s versatility was further verified by purifying a mixture of laccase enzyme and by removing the used organic solvents from various carriers (e.g., lipid-based, polymeric, and protein nanoparticles). It is envisioned that the outstanding performance of ultrafast dialysis will enables a continuous-flow downstream process for diverse nano-carriers by intensifying with extra steps in the manufacturing of nanomedicnes, including targeted drug delivery and cancer therapy.

MPS blockade with liposomes controls pharmacokinetics of nanoparticles in a size-dependent manner

Pharmacokinetics of nanomedicines can be improved by a temporal blockade of mononuclear phagocyte system (MPS) through the interaction with other biocompatible nanoparticles. Liposomes are excellent candidates as blocking agents, but the efficiency of the MPS blockade can greatly depend on the liposome properties. Here, we investigated the dependence of the efficiency of the induced MPS blockadein vitroandin vivoon the size of blocking liposomes in the 100-500 nm range. Saturation of RAW 264.7 macrophage uptake was observed for phosphatidylcholine/cholesterol liposomes larger than 200 nmin vitro. In mice, liposomes of all sizes exhibited a blocking effect on liver macrophages, prolonging the circulation of subsequently administrated magnetic nanoparticles in the bloodstream, reducing their liver uptake, and increasing accumulation in the spleen and lungs. Importantly, these effects became more pronounced with the increase of liposome size. Optimization of the size of the blocking liposomes holds the potential to enhance drug delivery and improve cancer therapy.

A visible light-activated azo-fluorescent switch for imaging-guided and light-controlled release of antimycotics

Azo switches are widely employed as essential components in light-responsive systems. Here, we develop an azo-fluorescent switch that is visible light-responsive and its light-responsive processes can be monitored using fluorescence imaging. Visible light irradiation promotes isomerization, accompanied by changes in fluorescence that enable the process to be monitored through fluorescence imaging. Furthermore, we document that the nanocavity size of liposome encapsulated nanoparticles containing azo changes in the isomerization process and show that this change enables construction of a light-responsive nanoplatform for optically controlled release of antimycotics. Also, natural light activation of nanoparticles of the switch loaded with an antimycotic agent causes death of Rhizoctonia solani. The results show that these nanoparticles can double the holding period in comparison to small molecule antimycotics. The strategy used to design the imaging-guided light-controlled nano-antimycotic release system can be applicable to protocols for controlled delivery of a wide variety of drugs.

Preparation and evaluation the effects of retinoic acid loaded proliposomal nanofibers on microbial biofilm inhibition

The electrospinning method involves the production of different drug delivery systems using various polymers. The production of proliposomes with electrospinning provides the hybridization of two novel drug delivery systems. Retinoic acid, also known as all-trans retinoic acid (ATRA), is a common and effective drug for acne therapy. This study aimed to prepare ATRA-loaded proliposomal nanofibers and evaluate their effectiveness on microbial biofilm inhibition. Blank and ATRA-loaded proliposomal nanofiber formulations were fabricated in various polyvinylpyrrolidone, phosphatidylcholine and cholesterol ratios. TEM images verified the rapid formation of the liposomes after the hydration of nanofibers. The vesicle size, polydispersity index and zeta potential values of self-assembled liposomes were measured. The vesicle size values were found to be 321.9–363.8 nm with PDI values varying between 0.332 and 0.511 and zeta potential values of (−16.8) to (−20.5)mV. ATRA-loaded proliposomal nanofibers provided higher bioadhesion (0.25 mJ/cm2) than the commercial cream (0.07 mJ/cm2). The short-term stability results showed that the initial characteristics remained for three months at 4 °C. The proposed ATRA-loaded self-assembled proliposomal system provided antibacterial, fungistatic or fungicidal effects superior to retinoic acid itself and inhibited biofilm formation in lower concentrations. This approach can combine the stability advantage of nanofibers in the dry state with the high effectiveness of liposomes in acne treatment presenting antibacterial and anti-biofilm-forming activity against Candida albicans and Cutibacterium acnes.

Development of liposomal amniotic mesenchymal stem cell metabolite products (AMSC-MP) loaded-scaffold for in vitro osteogenesis induction

The use of scaffolds with good biocompatibility and mechanical properties largely determines the success of bone defect therapy intended to improve quality-adjusted life years. Furthermore, amniotic mesenchymal stem cell metabolite product (AMSC-MP) is required to accelerate bone regeneration with sustained release required to maximize the effectiveness of therapy. This study aims to evaluate the effect of different phospholipids on the osteogenesis capacity of AMSC-MP liposome loaded into scaffold. The thin layer hydration method was employed to create the AMSC-MP liposomes which had different lipid components: L-α-phosphatidylcholine (PC) an unsaturated or hydrogenated soybean phosphatidylcholine (HSPC), a saturated phospholipid, with different types of charged phospholipids i.e., 1,2-dioleoyltrimethylammoniumpropane (DOTAP) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), which were cationic and non-ionic lipids respectively.AMSC-MP liposomes were embedded in the scaffold during a 24-hour incubation period. The results indicated that the particle sizes of liposomes prepared with saturated phospholipids, HS-DOTAP (132.35 ± 2.75 nm) and HS-DOTAP (152.85 ± 5.86 nm) were larger than those with saturated phospholipids, namely PC-DOTAP (139.355 ± 2.75 nm) and PC-DOTAP (91.85 ± 0.07 nm). The use of DOTAP in AMSC-liposomes resulted in positively charged vesicles i.e., +5 mV for HSPC-DOTAP and +10 mV for PC-DOTAP. Moreover, the results of an MTT viability test conducted on 7f2 cells and MSC indicated that all the formulas demonstrate good in vitro biocompatibility. Formulations containing DOPE produced high cellular uptake values and had superior sustain release properties compared to the others. This result correlates positively with cell attachment to the liposome scaffold which was higher than the others. Moreover, DOPE-containing formulations increased RUNX2 expression, indicating enhanced in vitro osteogenesis capacity. Therefore, Liposome AMSC-MP loaded scaffold demonstrates high potential for use in bone regeneration therapy.

Improving Skin Cancer Treatment by Dual Drug Co-Encapsulation into Liposomal Systems-An Integrated Approach towards Anticancer Synergism and Targeted Delivery.

Skin cancer is a high-incidence complex disease, representing a significant challenge to public health, with conventional treatments often having limited efficacy and severe side effects. Nanocarrier-based systems provide a controlled, targeted, and efficacious methodology for the delivery of therapeutic molecules, leading to enhanced therapeutic efficacy, the protection of active molecules from degradation, and reduced adverse effects. These features are even more relevant in dual-loaded nanosystems, with the encapsulated drug molecules leading to synergistic antitumor effects. This review examines the potential of improving the treatment of skin cancer through dual-loaded liposomal systems. The performed analysis focused on the characterization of the developed liposomal formulations' particle size, polydispersity index, zeta potential, encapsulation efficiency, drug release, and in vitro and/or in vivo therapeutic efficacy and safety. The combination of therapeutic agents such as doxorubicin, 5-fluorouracil, paclitaxel, cetuximab, celecoxib, curcumin, resveratrol, quercetin, bufalin, hispolon, ceramide, DNA, STAT3 siRNA, Bcl-xl siRNA, Aurora-A inhibitor XY-4, 1-Methyl-tryptophan, and cytosine-phosphate-guanosine anionic peptide led to increased and targeted anticancer effects, having relevant complementary effects as well, including antioxidant, anti-inflammatory, and immunomodulatory activities, all relevant in skin cancer pathophysiology. The substantial potential of co-loaded liposomal systems as highly promising for advancing skin cancer treatment is demonstrated.

Impact of formulation parameters and circulation time on PEGylated liposomal doxorubicin related hand-foot syndrome

PEGylated liposomal doxorubicin (PLD) has effectively reduced the cardiac toxicity of free doxorubicin (DOX) due to its unique nanoscale properties. However, an unexpected accumulation of PLD in the skin has led to hand-foot syndrome (HFS), negatively impacting quality of life and psychological well-being. In this study, self-limiting HFS rat models were created to mimic human symptoms through varying dosing schedules and intensities of PLD. The effects of PLD formulation parameters on HFS were also investigated. The results demonstrated that replacing ammonium sulfate with citric buffer, increasing liposome size, or reducing DSPE-mPEG2000 modification density alleviated HFS. Additionally, liposomes without DSPE-mPEG2000 modification completely avoided HFS, suggesting that PEGylated phospholipid was the key formulation parameter contributing to PLD-induced HFS. Furthermore, the correlation between liposome pharmacokinetics and HFS indicated that PEGylation, rather than the extended circulation time of liposomes, may mediated PLD-related HFS. Better understanding of the formulation parameters that trigger HFS can guide reformulation strategies to mitigate or prevent this syndrome.

Can We Simplify Liposome Manufacturing Using a Complex DoE Approach?

Microfluidic liposome production presents a streamlined pathway for expediting the translation of liposomal formulations from the laboratory setting to clinical applications. Using this production method, resultant liposome characteristics can be tuned through the control of both the formulation parameters (including the lipids and solvents used) and production parameters (including the production speed and mixing ratio). Therefore, the aim of this study was to investigate the relationship between not only total flow rate (TFR), the fraction of the aqueous flow rate over the organic flow rate (flow rate ratio (FRR)), and the lipid concentration, but also the solvent selection, aqueous buffer, and production temperature. To achieve this, we used temperature, applying a design of experiment (DoE) combined with machine learning. This study demonstrated that liposome size and polydispersity were influenced by manipulation of not only the total flow rate and flow rate ratio but also through the lipids, lipid concentration, and solvent selection, such that liposome attributes can be in-process controlled, and all factors should be considered within a manufacturing process as impacting on liposome critical quality attributes.

The electro-responsive nanoliposome as an on-demand drug delivery platform for epilepsy treatment

Nano-based drug delivery systems are regarded as a promising tool for efficient epilepsy treatment and seizure medication with the least general side effects and socioeconomic challenges. In the current study, we have designed a smart nanoscale drug delivery platform and applied it in the kindling model of epilepsy that is triggered rapidly by epileptic discharges and releases anticonvulsant drugs in situ, such as carbamazepine (CBZ). The CBZ-loaded electroactive ferrocene nanoliposomes had an average diameter of 100.6 nm, a surface charge of −7.08 mV, and high drug encapsulation efficiency (85.4 %). A significant increase in liposome size was observed in response to direct current (50–500 μA) application. This liposome-based drug delivery system can release CBZ at a fast rate in response to both direct current and pulsatile electrical stimulation in vitro. The CBZ-liposome can release the anticonvulsant drug upon epileptiform activity in the kindled rat model and can decline electrographic and behavioral seizure activity in response to electrical stimulation of the hippocampus with an initially subconvulsive current. With satisfactory biosafety results, this “smart” nanocarrier has promising potential as an effective and safe drug delivery system to improve the therapeutic index of antiepileptic drugs.

Surfactant-Mediated Assembly of Precision-Size Liposomes.

Liposomes can greatly improve the pharmacokinetics of therapeutic agents due to their ability to encapsulate drugs and accumulate in target tissues. Considerable effort has been focused on methods to synthesize these nanocarriers in the past decades. However, most methods fail to controllably generate lipid vesicles at specific sizes and with low polydispersity, especially via scalable approaches suitable for clinical product manufacturing. Here, we report a surfactant-assisted liposome assembly method enabling the precise production of monodisperse liposomes with diameters ranging from 50 nm to 1 μm. To overcome scalability limitations, we used tangential flow filtration, a scalable size-based separation technique, to readily concentrate and purify the liposomal samples from more than 99.9% of detergent. Further, we propose two modes of liposome self-assembly following detergent dilution to explain the wide range of liposome size control, one in which phase separation into lipid-rich and detergent-rich phases drives the formation of large bilayer liposomes and a second where the rate of detergent monomer partitioning into solution controls bilayer leaflet imbalances that promote fusion into larger vesicles. We demonstrate the utility of controlled size assembly of liposomes by evaluating nanoparticle uptake in macrophages, where we observe a clear linear relationship between vesicle size and total nanoparticle uptake.

Incorporation of short-chain alcohols into fluid bilayers and its effect on membrane dynamic properties as seen by neutron scattering

In this work, we investigate the effect of concentrated alcoholic solutions (up to 40%w) on extruded 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) liposomes using scattering techniques. Extrusion in alcoholic aqueous solutions (methanol, ethanol, or butanol) reduces liposome size, evidenced from the decrease in hydrodynamic radius (RH) obtained from dynamic light scattering. Short-chain alcohols such as ethanol and butanol soften the lipid membranes, as observed by the decrease of the unrelaxed bending modulus (κ̃ ) obtained by neutron spin-echo spectroscopy. Thus, softer membranes are easily ruptured during extrusion, leading to a reduction in vesicle radius corroborated by a reduction in both RH and radius of gyration as seen by dynamic and static light scattering. Moreover, model-free analysis of small-angle neutron scattering (SANS) curves suggests that solvent molecules become incorporated into the lipid membrane. Analysing deviations in the scattering invariant from values predicted by mass balance, we find that the volume fraction of liposomes increases, modifying the scattering length density of the assemblies. By quantifying these changes, we estimate that 12% to 18% of the liposome membrane is composed of solvent molecules (alcohol + water), depending on the type of alcohol and its concentration present in solution, with the exception of glycerol where next to no incorporation was observed. Finally, structural parameters obtained through light scattering and changes in contrast profiles calculated from analysis of the invariant were corroborated through modelling of the SANS curves. Modelling suggests that a reduction of bilayer thickness takes place for liposomes dispersed in ethanolic and butanolic solutions, but not in the presence of methanol or glycerol.